Kymera Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $2,860 | $2,764 | $11,476 | $22,100 |
Gross Profit | 79,038 | -71,330 | 9,392 | 22,100 |
EBITDA | -85,152 | -79,326 | -74,422 | -63,461 |
EBIT | -87,184 | -82,175 | -76,506 | -65,509 |
Net Income | -87,030 | -82,175 | -76,614 | -65,581 |
Net Change In Cash | 2,860 | 2,764 | 11,476 | 22,100 |
Free Cash Flow | -66,853 | -27,291 | -60,579 | -79,617 |
Cash | 357,011 | 112,949 | 335,816 | 89,966 |
Basic Shares | 84,390 | 87,300 | 80,449 | 80,146 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $39,200 | $47,072 | $78,592 | $46,826 |
Gross Profit | 39,200 | 47,072 | 78,592 | 46,826 |
EBITDA | -303,061 | -216,236 | -143,201 | -151,655 |
EBIT | -311,374 | -223,609 | -146,766 | -154,632 |
Net Income | -311,400 | -223,858 | -146,962 | -154,808 |
Net Change In Cash | 39,200 | 47,072 | 78,592 | 46,826 |
Cost of Revenue | 20,433 | |||
Free Cash Flow | -234,340 | -207,339 | -137,305 | -155,921 |
Cash | 357,011 | 120,256 | 109,966 | 68,395 |
Basic Shares | 84,390 | 75,043 | 58,365 | 53,933 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$0.98 |
2025-09-30 | -$0.94 |
2025-06-30 | -$0.95 |
